Research advances in dual-conversion therapy for hepatocellular carcinoma

Area of Science:

• Hepatobiliary Surgery
• Surgical Oncology
• Gastroenterology

Background:

• Hepatocellular carcinoma (HCC) presents significant global health challenges, with many patients diagnosed at advanced stages.
• Conventional treatments for advanced HCC often have limited efficacy, especially for patients with large tumors or insufficient liver volume.
• Improved strategies are needed to enhance surgical resectability and patient prognosis in HCC.

Purpose of the Study:

• To review recent advancements and clinical applications of dual conversion therapy for hepatocellular carcinoma (HCC).
• To analyze the potential and challenges of dual conversion therapy in improving HCC surgical resectability and patient outcomes.
• To provide theoretical foundations and practical guidance for comprehensive HCC management.

Main Methods:

• Dual conversion therapy integrates tumor biological transformation (molecular targeted therapy, immunotherapy) with residual liver volume transformation (portal vein embolization, portal vein ligation).
• This strategy aims to simultaneously control tumor progression and augment postoperative hepatic functional reserve.
• The review synthesizes current research on dual conversion therapy's efficacy and application in HCC.

Main Results:

• Dual conversion therapy shows promise in managing advanced HCC by addressing both tumor burden and liver function.
• The integrated approach may enhance the feasibility of surgical resection for previously unresectable HCC cases.
• Further research is ongoing to optimize this strategy and overcome existing challenges.

Conclusions:

• Dual conversion therapy represents an innovative approach for advanced hepatocellular carcinoma (HCC).
• This strategy holds potential for improving surgical resectability rates and overall prognosis in HCC patients.
• Continued research and clinical application are crucial for refining dual conversion therapy in HCC management.